41 results on '"von Minckwitz G"'
Search Results
2. Evaluation of neutrophil gelatinase-associated lipocalin (NGAL) as predictor of response to neoadjuvant chemotherapy (NACT) in primary breast cancer.
3. Predictive value of sphingosine kinase-1 expression in neoadjuvant treatment of breast cancer.
4. A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC).
5. Separation of breast cancer from normal tissues using GC-MS-based metabolite profiling.
6. A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients: Randomized European Celecoxib Trial (REACT).
7. Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study.
8. Sentinel-node biopsy before or after neoadjuvant systemic treatment: The German SENTINA trial.
9. Identification of thymosin beta 15 A (TMSB15A) mRNA expression as a predictor for response to neoadjuvant chemotherapy in patients with operable breast cancer.
10. PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy.
11. Molecular types and prognostic markers uPA/PAI-1 for 2,497 early breast cancer patients in the multicenter, randomized NNBC 3-Europe trial.
12. ICE II: An investigational randomized phase II study on epirubicin (E) plus cyclophospamide (C) (or CMF) versus nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly nonfrail patients with an increased risk for relapse of a primary carcinoma of the breast.
13. Geparquinto: An interim safety analysis of epirubicin/cyclophosphamide followed by docetaxel with or without bevacizumab as neoadjuvant chemotherapy for primary breast cancer patients
14. Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer
15. Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): Final results and analysis of markers predicting response to treatment
16. ASCO-recommended prognostic factors uPA/PAI-1 in node-negative (N0) breast cancer patients (pts) compared to clinicopathological risk assessment within the NNBC 3-Europe trial
17. Gain study: A phase III trial to compare ETC versus EC-TX and ibandronate versus observation in patients with node-positive primary breast cancer
18. Evaluating the impact of relative total dose intensity (RTDI) on patient's short- and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer: A pooled analysis
19. Evaluation of tumor-associated lymphocytes as a predictor of response to neoadjuvant chemotherapy in breast cancer: Results from the GeparDuo and GeparTrio trial
20. Contribution of tumor-associated lymphocytes to a niche for “stem cell-like” breast cancer cells
21. PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery
22. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05)
23. Breast cancer during pregnancy—A prospective and retrospective European registry (GBG-20/BIG02–03)
24. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 for improved management in node-negative (N0) breast cancer: Experiences from the ongoing multicenter trial NNBC 3-Europe
25. Mitomycin C in combination with capecitabine (Mi-Cap) as chemotherapy in breast cancer patients with extensive liver metastases and impaired hepatic function: A non-randomized multicentre phase II study
26. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)
27. Breast cancers with stem cell-like features delineate endocrine responsiveness
28. Oblimersen (O) in combination with docetaxel (T), adriamycin (A), and cyclophosphamide (C) as neoadjuvant systemic therapy (NST) in primary breast cancer (PBC): Final results of a multicentric phase I study
29. Toxicity in elderly breast cancer patients treated by a taxane based chemotherapy as adjuvant or neoadjuvant therapy for primary breast cancer
30. Survival benefit of switching to anastrozole after 2 years’ treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study
31. c-kit: Identification of co-regulated genes by gene expression profiling and clinical relevance of two breast cancer subtypes with stem cell like features
32. Comparison of neoadjuvant 6 vs 8 cycles of docetaxel/doxorubicin/cyclophosphamide (TAC) in patients early responding to TACx2-the GEPARTRIO Study
33. BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC)
34. Clonidine vs. venlafaxine as treatment for hot flashes in breast cancer patients: A double-blind randomised study
35. Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide (TAC) in breast cancer patients
36. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, doxorubicin, and cyclophosphamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures
37. TAC as neoadjuvant chemotherapy in patients with primary breast cancer - interim progress report on 907 cases of the randomized prospective Gepartrio-trial
38. TAC as neoadjuvant chemotherapy in patients with primary breast cancer - interim progress report on 907 cases of the randomized prospective Gepartrio-trial
39. Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 trial
40. Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 trial
41. Prospective randomized studies are needed to define the role of axillary lymph node dissection in primary breast cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.